查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1390665

宠物癌症治疗市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Pet Cancer Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年，全球宠物癌症治疗市场规模达到2.686亿美元。展望未来， IMARC Group预计到2028年该市场将达到4.731亿美元，2022-2028年复合年增长率（CAGR）为9.89%。宠物拥有率的提高和人类与动物之间的联繫、兽医学和研究的进步以及人们对宠物癌症疗法的可用性和益处的认识不断提高是推动市场的一些主要因素。

宠物癌症疗法是一种专门的医疗疗法和药物，旨在诊断、治疗和控制动物（特别是狗和猫）的癌症。与人类癌症治疗类似，这些疗法可能包括化疗、放射治疗、免疫疗法、标靶治疗和安宁疗护。兽医肿瘤学家使用这些疗法来治疗宠物的各种癌症并提高它们的生活品质。随着兽医学的不断进步，宠物癌症疗法的可用性和有效性不断提高，使宠物主人能够为他们心爱的被诊断患有癌症的动物伙伴获得全面和富有同情心的护理。

由于宠物拥有量和人与动物关係的增加，宠物主人投资先进医疗（包括癌症治疗）的意愿不断增强，以确保动物伙伴的福祉，这将刺激预测期内市场的成长。此外，由于诊断能力的提高和寿命的延长，宠物癌症盛行率不断上升，增加了对有效和专业治疗的需求。除此之外，兽医肿瘤学和研究的许多进步，包括为宠物开发更有针对性和创新的癌症疗法，促进了市场的成长。此外，宠物主人对宠物癌症治疗的可用性和益处的认识不断提高，导致了早期检测和干预，推动了市场成长。此外，专门的兽医肿瘤中心的建立以及兽医和人类肿瘤学家之间不断加强的合作，提高了宠物癌症护理的可及性和专业知识，也促进了市场的成长。

宠物癌症治疗市场趋势/驱动因素：

增加宠物饲养量和人与动物的联繫

宠物数量的增加和人类与动物关係的加强已成为宠物癌症治疗市场的重要驱动力。随着越来越多的家庭欢迎宠物进入他们的生活，这些伴侣动物被广泛认为是珍贵的家庭成员。这种情感连结培养了宠物主人的深刻责任感，以确保毛茸茸的同伴的福祉和健康。因此，宠物主人越来越愿意投资先进的癌症治疗方法来对抗疾病并提高宠物的生活品质。宠物主人为他们的宠物寻求尽可能最好的护理，导致对有效的癌症治疗方法的需求增加，这些治疗方法可以减轻宠物的痛苦并延长宠物的生命。

兽医肿瘤学的进展

近年来，由于技术进步和研究突破，兽医肿瘤学领域取得了显着进展。改进的诊断技术可以实现早期、准确的癌症检测，使兽医能够及时启动治疗。此外，人们对宠物癌症生物学认识的提升为标靶治疗、免疫疗法和新型治疗方式打开了大门。兽医肿瘤学家现在拥有一个扩展的癌症治疗工具箱，有助于制定适合每隻宠物独特状况的个人化护理计划。这些进步为面临癌症诊断的宠物主人带来了希望，并鼓励他们探索和选择先进且有效的癌症疗法。

不断增长的兽医医疗保健支出

人们对宠物的看法从单纯的动物伙伴转变为重要的家庭成员，导致兽医医疗保健支出模式显着转变。今天的宠物主人比以往任何时候都更愿意分配大量的财政资源来确保他们的宠物的健康和长寿。人们对现有癌症治疗方案的认识不断增强，以及对提供最佳护理的渴望，推动了宠物癌症治疗支出的增加。主人愿意投资最新、最有效的癌症治疗方法来对抗这种疾病，并改善毛茸茸的同伴的整体健康和幸福感。兽医医疗保健支出的激增进一步推动了宠物癌症治疗市场的发展，为宠物先进癌症治疗方案的研究、创新和开发创造了机会。

宠物癌症治疗产业细分：

IMARC Group提供了全球宠物癌症治疗市场报告各细分市场主要趋势的分析，以及 2023-2028 年全球、区域和国家层面的预测。我们的报告根据治疗、动物种类、癌症类型和最终用户对市场进行了分类。

治疗分手：

化疗

放射治疗

免疫疗法

联合疗法

其他的

化疗占据市场主导地位

该报告根据该疗法对市场进行了详细的细分和分析。这包括化疗、放射治疗、免疫治疗、合併治疗等。根据该报告，化疗占最大部分。

化疗被广泛用作各种宠物癌症的标准治疗方法。作为一种有效且有系统的方法，化疗针对快速分裂的癌细胞，抑制其生长和扩散。它能够治疗多种癌症，包括淋巴瘤、肥大细胞肿瘤和骨肉瘤，使其成为兽医肿瘤学家的多功能且必不可少的治疗选择。

此外，兽医学的进步导致了更有针对性和毒性较小的化疗方案的开发，减少了不良反应并提高了接受治疗的宠物的整体生活品质。宠物癌症病例的盛行率不断增加，加上宠物主人对可用治疗方案的认识不断提高，进一步促进了化疗领域的扩大。

依动物种类划分：

猫

小狗

其他的

狗在市场上占有最大份额

报告还根据动物种类对市场进行了详细的细分和分析。这包括猫、狗和其他。报告称，狗占据了最大的市场。

狗对各种类型的癌症有更高的易感性，这与人类的情况相似。作为一种受欢迎的伴侣动物，狗经常受到淋巴瘤、黑色素瘤和乳腺癌等癌症的影响。狗和人类在癌症生物学和肿瘤类型方面的相似性使狗成为研究癌症治疗的宝贵模型，从而导致治疗方法的进步，使这两个物种都受益。在狗身上进行的兽医肿瘤学研究导致了标靶疗法、免疫疗法和可转化为人类医学的新型治疗方式的发展。此外，宠物主人和他们的狗之间强烈的情感纽带促进了投资于他们的医疗保健（包括癌症治疗）的意愿，从而推动了对有效宠物癌症治疗的需求。

按癌症类型划分：

淋巴瘤

肥大细胞癌

黑色素瘤

乳癌和鳞状细胞癌

其他的

肥大细胞癌是最常见的癌症类型

该报告根据癌症类型对市场进行了详细的细分和分析。这包括淋巴瘤、肥大细胞癌、黑色素瘤、乳癌和鳞状细胞癌等。根据该报告，肥大细胞癌占最大部分。

肥大细胞肿瘤是狗最常见的皮肤癌之一，影响各个品种和年龄层。它们的不同行为和对治疗的不同反应需要专门的治疗方法来进行有效的管理。兽医肿瘤学家正在不断研究和开发专门针对肥大细胞癌的标靶疗法和免疫疗法。因此，宠物癌症治疗肥大细胞肿瘤的进步使狗受益，并有助于更广泛地了解和治疗人类肥大细胞相关疾病。宠物主人对早期检测和综合治疗方案需求的认识不断提高，进一步推动了对创新和高效宠物癌症疗法的需求。

按最终用户划分：

兽医医院和临床药房

零售药局

网路药局

其他的

兽医医院和临床药房占据最大市场份额

该报告根据最终用户对市场进行了详细的细分和分析。这包括兽医医院和临床药房、零售药房、线上药房等。报告称，兽医医院和临床药房是最大的细分市场。

兽医医院和临床药房作为专业宠物癌症药物和疗法的主要分销和治疗中心，在推动宠物癌症治疗市场方面发挥着至关重要的作用。这些机构为宠物主人提供了一个获得各种癌症治疗的集中平台，包括化疗药物、标靶治疗和免疫疗法。兽医院与製药公司和研究机构合作，随时了解宠物癌症治疗的最新进展，为患者提供尖端的治疗选择。这些设施内的临床药房确保准确的药物配发和给药，并遵守精确的剂量和治疗方案。他们在处理宠物癌症治疗和提供个人化护理方面的专业知识有助于改善治疗结果，并增强宠物主人为他们心爱的动物伙伴寻求最佳癌症护理的信心，最终推动宠物癌症治疗市场的成长。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美在市场上表现出明显的主导地位

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）、亚太地区（中国、日本、印度、韩国、澳洲、印尼等）、欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）拉丁美洲（巴西、墨西哥等）、中东和非洲。报告称，北美占据最大的市场份额。

北美占据了最大的市场份额，因为该地区养宠物的比例很高，而且宠物主人和他们的动物之间有很强的联繫，导致他们更愿意投资于医疗保健，包括癌症治疗。北美也处于兽医学和肿瘤学研究进步的前沿，从而开发了创新和有针对性的宠物癌症疗法。该地区的兽医医院和研究机构与製药公司密切合作，进行临床试验并向市场推出尖端治疗方法。此外，完善的兽医医疗保健基础设施的存在和个人化宠物护理的不断增长趋势也促进了对专业且有效的癌症治疗的需求。这些因素共同推动了北美宠物癌症治疗市场的成长，使其成为该行业的领先地区。

竞争格局：

近年来，该市场正在稳步增长，因为各个主要参与者都专注于开发针对特定类型宠物癌症的标靶疗法和免疫疗法，旨在提高治疗效果并减少副作用。领先企业在精准医学方面取得的众多进步导致了遗传和分子生物标记的识别，从而实现了个人化治疗方法。此外，製造商正在探索新型药物递送方法，例如奈米颗粒和脂质体，以提高药物稳定性并增强肿瘤渗透。人工智慧 (AI) 和机器学习 (ML) 等新兴技术在宠物癌症研究中的整合正在彻底改变资料分析并加速药物发现过程。我们也预期市场将见证新进业者、产品组合的整合、研发 (R&D) 计画的增加以及策略合作的增加，以推动宠物癌症治疗领域内的健康竞争。

该报告对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。市场上的一些主要参与者包括：

AB科学

勃林格殷格翰国际股份有限公司

Elanco 动物保健公司

埃利亚斯动物保健有限责任公司

核药疗法

辉瑞公司

雷杰纽斯有限公司

Rhizen 製药公司

托瑞根製药公司

兽医DC公司

维克

硕腾公司

最近的发展：

2023年7月，领先的製药公司勃林格殷格翰国际有限公司的创新产品NexGard PLUS获得美国食品药物管理局（FDA）的批准。宠物保健领域的这一突破性进步推出了一种咀嚼片，专门用于保护狗免受体内和体外寄生虫的侵害。该片剂含有多种活性成分的强大组合，包括阿福拉纳、莫昔克丁和噻嘧啶，它们协同作用，提供对常见寄生虫威胁的全面保护。

2022 年 12 月，着名动物保健公司 Elanco Animal Health Incorporated 宣布取得突破性成就，FDA 批准了 Bexacat（贝格列净片剂）。 Bexacat 作为第一个针对猫糖尿病的口服治疗选择，标誌着一个重要的里程碑。这种开创性的药物引入了一种治疗猫糖尿病的新方法，解决了兽医行业未满足的医疗需求。 Bexacat 是一种易于服用的片剂，为猫科动物糖尿病管理提供了一个有前途的解决方案，为兽医和宠物主人提供了传统胰岛素注射的有效且方便的替代方案。

2021 年 11 月，专门从事宠物癌症治疗的领先生物技术公司 ELIAS Animal Health LLC 宣布在溶瘤病毒疗法领域取得重大进展。该公司已成功获得 Genelux Corporation 的尖端溶瘤痘苗病毒治疗的独家许可。这种突破性的治疗方法利用改良的痘苗病毒来瞄准并摧毁宠物动物的癌细胞。透过利用病毒复製和感染癌细胞的固有能力，同时不伤害健康组织，这种疗法提供了一种对抗各种类型宠物癌症的新方法。

本报告回答的关键问题

  • 2022年全球宠物癌症治疗市场规模有多大
  • 2023-2028年全球宠物癌症治疗市场的预期成长率是多少
  • 推动全球宠物癌症治疗市场的关键因素是什么
  • COVID-19 对全球宠物癌症治疗市场有何影响
  • 基于治疗的全球宠物癌症治疗市场的细分是什么
  • 基于动物物种的全球宠物癌症治疗市场的细分是什么
  • 根据癌症类型，全球宠物癌症治疗市场的细分如何
  • 基于最终用户的全球宠物癌症治疗市场的细分是什么
  • 全球宠物癌症治疗市场的关键区域有哪些
  • 10. 全球宠物癌症治疗市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 2022 年全球宠物癌症治疗市场规模有多大？
  • 2023-2028年全球宠物癌症治疗市场的预期成长率是多少？
  • 推动全球宠物癌症治疗市场的关键因素是什么？
  • COVID-19 对全球宠物癌症治疗市场有何影响？
  • 基于此疗法的全球宠物癌症治疗市场的细分情况如何？
  • 基于动物物种的全球宠物癌症治疗市场的细分情况如何？
  • 根据癌症类型，全球宠物癌症治疗市场的细分如何？
  • 基于最终用户的全球宠物癌症治疗市场的细分情况如何？
  • 全球宠物癌症治疗市场的关键地区有哪些？
  • 谁是全球宠物癌症治疗市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球宠物癌症治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：透过疗法进行市场区隔

  • 化疗
    • 市场走向
    • 市场预测
  • 放射治疗
    • 市场走向
    • 市场预测
  • 免疫疗法
    • 市场走向
    • 市场预测
  • 联合疗法
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：以动物种类分類的市场

  • 猫
    • 市场走向
    • 市场预测
  • 小狗
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：按癌症类型分類的市场区隔

  • 淋巴瘤
    • 市场走向
    • 市场预测
  • 肥大细胞癌
    • 市场走向
    • 市场预测
  • 黑色素瘤
    • 市场走向
    • 市场预测
  • 乳癌和鳞状细胞癌
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：最终用户的市场区隔

  • 兽医医院和临床药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：按地区分類的市场细分

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AB Science
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • ELIAS Animal Health LLC
    • Karyopharm Therapeutics
    • Pfizer Inc.
    • Regeneus Ltd.
    • Rhizen Pharmaceuticals AG
    • Torigen Pharmaceuticals Inc.
    • VetDC Inc.
    • Virbac
    • Zoetis Inc.
Product Code: SR112023A4472

Abstract

The global pet cancer therapeutics market size reached US$ 268.6 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 473.1 Million by 2028, exhibiting a growth rate (CAGR) of 9.89% during 2022-2028. The increasing pet ownership rates and human-animal bond, advancements in veterinary medicine and research, and growing awareness about the availability and benefits of pet cancer therapeutics are some of the major factors propelling the market.

Pet cancer therapeutics are specialized medical treatments and drugs designed to diagnose, treat, and manage cancer in animals, particularly in dogs and cats. Similar to cancer treatments in humans, these therapeutics may include chemotherapy, radiation therapy, immunotherapy, targeted therapies, and palliative care. Veterinary oncologists administer these therapies to address various types of cancer in pets and improve their quality of life. As advancements in veterinary medicine continue, the availability and effectiveness of pet cancer therapeutics have increased, allowing pet owners to access comprehensive and compassionate care for their beloved animal companions diagnosed with cancer.

The rising willingness among pet owners to invest in advanced medical treatments, including cancer therapeutics, to ensure the well-being of their animal companions due to the increasing pet ownership and human-animal bond, will stimulate the growth of the market during the forecast period. Moreover, the growing prevalence of cancer in pets, owing to improved diagnostic capabilities and prolonged lifespan has augmented the demand for effective and specialized treatments. Apart from this, numerous advancements in veterinary oncology and research, including the development of more targeted and innovative cancer therapies for pets, have catalyzed the market growth. Additionally, the heightening awareness among pet owners about the availability and benefits of pet cancer therapeutics has led to early detection and intervention, propelling the market growth. Furthermore, the establishment of specialized veterinary oncology centers and the rising collaborations between veterinary and human oncologists that improve the accessibility and expertise in pet cancer care are contributing to the market growth.

Pet Cancer Therapeutics Market Trends/Drivers:

Increasing pet ownership and human-animal bond

The rise in pet ownership and the strengthening human-animal bond have become significant drivers in the market for pet cancer therapeutics. As more households welcome pets into their lives, these companion animals are widely considered cherished family members. This emotional connection fosters a deep sense of responsibility among pet owners to ensure the well-being and health of their furry companions. Consequently, there is a growing willingness among pet owners to invest in advanced cancer treatments to combat the disease and enhance the quality of life for pets. Pet owners seek the best possible care for their pets, leading to an increased demand for effective cancer therapeutics that can alleviate suffering and prolong their pets' lives.

Advancements in veterinary oncology

The field of veterinary oncology has witnessed remarkable progress in recent years, owing to technological advancements and research breakthroughs. Improved diagnostic techniques enable early and accurate cancer detection, empowering veterinarians to initiate timely treatment. Moreover, the rise in understanding of cancer biology in pets has opened doors to targeted therapies, immunotherapies, and novel treatment modalities. Veterinary oncologists now have an expanded toolbox of cancer treatments, facilitating the development of personalized care plans tailored to each pet's unique condition. These advancements instill hope in pet owners facing a cancer diagnosis for their beloved animals and encourage them to explore and opt for advanced and effective cancer therapies.

Growing veterinary healthcare expenditure

The changing perception of pets from mere animal companions to valued family members has led to a notable shift in spending patterns on veterinary healthcare. Pet owners today are more willing than ever to allocate substantial financial resources to ensure their pets' well-being and longevity. The growing awareness of available cancer treatment options and the desire to provide the best possible care have driven the increase in expenditure on pet cancer therapeutics. Owners are willing to invest in the latest and most effective cancer treatments to combat the disease and improve the overall health and happiness of their furry companions. This surge in veterinary healthcare spending further propels the pet cancer therapeutics market, creating opportunities for research, innovation, and the development of advanced cancer treatment options for pets.

Pet Cancer Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pet cancer therapeutics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on therapy, animal species, cancer type and end user.

Breakup by Therapy:

Chemotherapy

Radiation Therapy

Immunotherapy

Combination Therapy

Others

Chemotherapy dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiation therapy, immunotherapy, combination therapy, and others. According to the report, chemotherapy represented the largest segment.

Chemotherapy is widely used as a standard treatment for various types of pet cancers. As a potent and systematic approach, chemotherapy targets rapidly dividing cancer cells, inhibiting their growth and spread. Its ability to treat a wide range of cancers, including lymphoma, mast cell tumors, and osteosarcoma, makes it a versatile and essential therapeutic option for veterinary oncologists.

Moreover, advancements in veterinary medicine have led to the development of more targeted and less toxic chemotherapy regimens, reducing adverse effects and improving the overall quality of life for pets undergoing treatment. The increasing prevalence of pet cancer cases, coupled with the growing awareness among pet owners about available treatment options, further contributes to the expansion of the chemotherapy segment.

Breakup by Animal Species:

Cats

Dogs

Others

Dogs hold the largest share in the market

A detailed breakup and analysis of the market based on the animal species has also been provided in the report. This includes cats, dogs, and others. According to the report, dogs accounted for the largest market share.

Dogs have a higher susceptibility to various types of cancers, mirroring human conditions. As a popular companion animal, dogs are commonly affected by cancers such as lymphoma, melanoma, and mammary tumors, among others. The similarities in cancer biology and tumor types between dogs and humans make dogs valuable models for studying cancer treatments, leading to advancements in therapeutic approaches that benefit both species. Veterinary oncology research conducted in dogs has resulted in the development of targeted therapies, immunotherapies, and novel treatment modalities that can be translated to human medicine. Furthermore, the strong emotional bond between pet owners and their dogs fosters a willingness to invest in their healthcare, including cancer treatments, thus driving the demand for effective pet cancer therapeutics.

Breakup by Cancer Type:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

Mast cell cancer represents the most popular type of cancer

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and others. According to the report, mast cell cancer represented the largest segment.

Mast cell tumors are one of the most common skin cancers in dogs, affecting various breeds and age groups. Their diverse behavior and variable response to treatments necessitate specialized therapeutics for effective management. Veterinary oncologists are continually researching and developing targeted therapies and immunotherapies specifically tailored to combat mast cell cancer. As a result, advancements in pet cancer therapeutics for mast cell tumors benefit dogs as well as contribute to the broader understanding and treatment of mast cell-related conditions in humans. The increasing awareness among pet owners about the need for early detection and comprehensive treatment options further drives the demand for innovative and efficient pet cancer therapeutics.

Breakup by End User:

Veterinary Hospitals and Clinical Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Veterinary hospitals and clinical pharmacies account for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes veterinary hospitals and clinical pharmacies, retail pharmacies, online pharmacies, and others. According to the report, veterinary hospitals and clinical pharmacies represented the largest segment.

Veterinary hospitals and clinical pharmacies play a crucial role in driving the pet cancer therapeutics market by serving as key distribution and treatment centers for specialized pet cancer drugs and therapies. These institutions provide a centralized platform for pet owners to access a wide range of cancer treatments, including chemotherapy agents, targeted therapies, and immunotherapies. Veterinary hospitals collaborate with pharmaceutical companies and research institutions to stay updated on the latest advancements in pet cancer therapeutics, offering cutting-edge treatment options to their patients. Clinical pharmacies within these facilities ensure accurate drug dispensing and administration, adhering to precise dosages and treatment protocols. Their expertise in handling pet cancer therapeutics and providing personalized care contributes to improved treatment outcomes and enhances pet owners' confidence in seeking optimal cancer care for their beloved animal companions, ultimately driving the growth of the pet cancer therapeutics market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and Others) Latin America (Brazil, Mexico and Others), Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a high prevalence of pet ownership, and there is a strong bond between pet owners and their animals, leading to a greater willingness to invest in their healthcare, including cancer treatment. North America is also at the forefront of advancements in veterinary medicine and oncology research, resulting in the development of innovative and targeted pet cancer therapeutics. Veterinary hospitals and research institutions in the region collaborate closely with pharmaceutical companies to conduct clinical trials and introduce cutting-edge treatments to the market. Additionally, the presence of well-established veterinary healthcare infrastructure and a growing trend of personalized pet care contribute to the demand for specialized and effective cancer therapies. These factors collectively drive the growth of the market for pet cancer therapeutics in North America, making it a leading region in the industry.

Competitive Landscape:

The market is experiencing steady growth in recent years as various key players are focusing on the development of targeted therapies and immunotherapies tailored to specific types of pet cancers, aiming to enhance treatment effectiveness and reduce side effects. Numerous advancements in precision medicine by leading players have led to the identification of genetic and molecular biomarkers, allowing for personalized treatment approaches. Additionally, novel drug delivery methods, such as nanoparticles and liposomes, are being explored by manufacturers to improve drug stability and enhance tumor penetration. The integration of emerging technologies like artificial intelligence (AI) and machine learning (ML) in pet cancer research is revolutionizing data analysis and accelerating drug discovery processes. We also expect the market to witness new entrants, consolidation of product portfolios, rise in research and development (R&D) initiatives, and increased strategic collaborations to drive healthy competition within the pet cancer therapeutics domain.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AB Science

Boehringer Ingelheim International GmbH

Elanco Animal Health Incorporated

ELIAS Animal Health LLC

Karyopharm Therapeutics

Pfizer Inc.

Regeneus Ltd.

Rhizen Pharmaceuticals AG

Torigen Pharmaceuticals Inc.

VetDC Inc.

Virbac

Zoetis Inc.

Recent Developments:

In July 2023, Boehringer Ingelheim International GmbH, a leading pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative product, NexGard PLUS. This groundbreaking advancement in pet healthcare introduces a chewable tablet specifically designed to safeguard dogs from both internal and external parasites. The tablet contains a powerful combination of active ingredients, including afoxolaner, moxidectin, and pyrantel, which work synergistically to provide comprehensive protection against common parasitic threats.

In Dec 2022, Elanco Animal Health Incorporated, a prominent animal health company, announced a groundbreaking achievement with the FDA approval of Bexacat (bexagliflozin tablets). Bexacat marks a significant milestone as the first-of-its-kind oral treatment option for feline diabetes. This pioneering medication introduces a novel approach to managing diabetes in cats, addressing an unmet medical need in the veterinary industry. Bexacat, formulated as easily administered tablets, offers a promising solution for feline diabetes management, providing veterinarians and pet owners with an effective and convenient alternative to traditional insulin injections.

In Nov 2021, ELIAS Animal Health LLC, a leading biotechnology company specializing in cancer therapeutics for pets, announced a significant development in the field of oncolytic virotherapy. The company has successfully obtained an exclusive in-license from Genelux Corporation for their cutting-edge Oncolytic Vaccinia Virus Treatment. This groundbreaking treatment utilizes a modified vaccinia virus to target and destroy cancer cells in pet animals. By leveraging the virus's inherent ability to replicate and infect cancer cells while sparing healthy tissues, this therapy offers a novel approach to combat various types of pet cancers.

Key Questions Answered in This Report

  • 1. What was the size of the global pet cancer therapeutics market in 2022?
  • 2. What is the expected growth rate of the global pet cancer therapeutics market during 2023-2028?
  • 3. What are the key factors driving the global pet cancer therapeutics market?
  • 4. What has been the impact of COVID-19 on the global pet cancer therapeutics market?
  • 5. What is the breakup of the global pet cancer therapeutics market based on the therapy?
  • 6. What is the breakup of the global pet cancer therapeutics market based on thej animal species?
  • 7. What is the breakup of the global pet cancer therapeutics market based on cancer type?
  • 8. What is the breakup of the global pet cancer therapeutics market based on the end user?
  • 9. What are the key regions in the global pet cancer therapeutics market?
  • 10. Who are the key players/companies in the global pet cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pet Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Immunotherapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Combination Therapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Animal Species

  • 7.1 Cats
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Dogs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Mast Cell Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Mammary and Squamous Cell Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Veterinary Hospitals and Clinical Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AB Science
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Elanco Animal Health Incorporated
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 ELIAS Animal Health LLC
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Karyopharm Therapeutics
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Pfizer Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Regeneus Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Rhizen Pharmaceuticals AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Torigen Pharmaceuticals Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 VetDC Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Virbac
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Zoetis Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pet Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Pet Cancer Therapeutics Market: Breakup by Therapy (in %), 2022
  • Figure 5: Global: Pet Cancer Therapeutics Market: Breakup by Animal Species (in %), 2022
  • Figure 6: Global: Pet Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2022
  • Figure 7: Global: Pet Cancer Therapeutics Market: Breakup by End User (in %), 2022
  • Figure 8: Global: Pet Cancer Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Pet Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Pet Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Pet Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Pet Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Pet Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Pet Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Pet Cancer Therapeutics (Combination Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Pet Cancer Therapeutics (Combination Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Pet Cancer Therapeutics (Other Therapies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Pet Cancer Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Pet Cancer Therapeutics (Cats) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Pet Cancer Therapeutics (Cats) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Pet Cancer Therapeutics (Dogs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Pet Cancer Therapeutics (Dogs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Pet Cancer Therapeutics (Other Animal Species) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Pet Cancer Therapeutics (Other Animal Species) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Pet Cancer Therapeutics (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Pet Cancer Therapeutics (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Pet Cancer Therapeutics (Melanoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Pet Cancer Therapeutics (Melanoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Pet Cancer Therapeutics (Other Cancer Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Pet Cancer Therapeutics (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Pet Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Pet Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Pet Cancer Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Pet Cancer Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: North America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: North America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: United States: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: United States: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Canada: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Canada: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Asia-Pacific: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Asia-Pacific: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: China: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: China: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Japan: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Japan: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: India: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: India: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: South Korea: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: South Korea: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Australia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Australia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Indonesia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Indonesia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Europe: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Europe: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Germany: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Germany: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: France: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: France: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: United Kingdom: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: United Kingdom: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Italy: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Italy: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Spain: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Spain: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Russia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Russia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Latin America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Latin America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Brazil: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Brazil: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Mexico: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Mexico: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Middle East and Africa: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Middle East and Africa: Pet Cancer Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 91: Middle East and Africa: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 92: Global: Pet Cancer Therapeutics Industry: SWOT Analysis
  • Figure 93: Global: Pet Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 94: Global: Pet Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pet Cancer Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
  • Table 3: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Animal Species (in Million US$), 2023-2028
  • Table 4: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2023-2028
  • Table 5: Global: Pet Cancer Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 6: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Pet Cancer Therapeutics Market: Competitive Structure
  • Table 8: Global: Pet Cancer Therapeutics Market: Key Players